Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00159653 | A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma | PHASE3 | COMPLETED | 500 | — | — | Jul 1, 2005 | Jun 1, 2007 | Feb 21, 2021 | 55 | United States, Canada |
| NCT00150267 | A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension | PHASE3 | COMPLETED | 976 | — | — | Feb 1, 2002 | - | Nov 5, 2008 | 74 | Australia, Belgium +10 |
| Name | Type | Description |
|---|---|---|
| Xalacom | DRUG | - |
| Xalatan | DRUG | - |
| Timolol | DRUG | - |
Inclusion Criteria: * Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening Exclusion Criteria: * Closed/ barely open anterior chamber...